Stop STALLING Act
Summary
Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug. The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
Bill status
in committee
1 of 4 stages cleared
Introduction
Apr 2021
Committee Review
Floor Vote
President
Introduced Apr 28, 2021
Last action Dec 8, 2021
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
5
Key actions
2
Committee
3
Dec 8, 2021
Upper · Passed
Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.
upper
Jul 29, 2021
Upper · Passed
Committee on the Judiciary. Ordered to be reported without amendment favorably.
upper
Apr 28, 2021
Committee
Read twice and referred to the Committee on the Judiciary.
upper
Apr 28, 2021
Introduced
Introduced in Senate
upper
1 primary · 9 co-sponsors
Sponsors
Ask Maddy
·
AI policy assistant
Ask Maddy about S 1425
Scope: US
Hi! I can help you understand S 1425. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline